You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
收購+增資 康惠製藥(603139.SH)斥916萬元獲菩豐堂藥業51%股權
格隆匯 05-20 18:46

格隆匯5月20日丨康惠製藥(603139.SH)宣佈,公司全資子公司康惠醫療擬0元受讓張雨、黎勇、黎英、沈傳玖及沈家勝所持四川菩豐堂藥業有限公司(簡稱“菩豐堂藥業”)共計30%的股權(對應630萬元出資額);在此前提下,康惠醫療擬向菩豐堂藥業增資916萬元,認購菩豐堂藥業900萬元新增註冊資本;該次交易完成後,菩豐堂藥業註冊資本將變為3000萬元,康惠醫療將持有其51%的股權。

菩豐堂藥業成立於2018年7月,主要業務為中藥材種植、收購及中藥飲片加工和銷售。該公司註冊資本2100萬元,註冊地址位於四川省都江堰市。公司依託四川地區豐富的中藥材資源優勢,主要圍繞道地中藥材,進行種植、加工和銷售。公司生產和銷售品種豐富,包括中藥材品種200多個、中藥飲片品規500多個、直接口服飲片10多個以及精緻罐裝中藥飲片20多個。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account